Search
Nervgen Pharma Ord Shs
NGENAdd to Watchlist
2.120USD
+0.030+1.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
171.78MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.44%
5 Days
+10.99%
1 Month
+6.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
Key Figures
2.110Open
2.220High
605.20KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
2.090Prev. Close
2.090Low
1.02MTurnover
--P/E Static
67.57P/B
0.00%Div Yield TTM
-228.63%ROA
6.30052wk High
1.29Volume Ratio
--Net Profit
79.65MShares
-0.4133EPS TTM
0.74Beta
-1207.46%ROE
1.50052wk Low
6.22%Amplitude
--Gross Margin
171.78MMarket Cap
2.26Reward/Risk
4.17%Risk Rate
TradingKey Stock Score of Nervgen Pharma Ord Shs
Currency: USD Updated: 2026-07-02Key Insights
Nervgen Pharma Ord Shs's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 220 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is relatively high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.67.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Nervgen Pharma Ord Shs's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Nervgen Pharma Ord Shs Highlights
StrengthsRisks
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Growing
The company is in a growing phase, with the latest annual income totaling USD 239.63K.
No Dividend
The company hasn't paid dividends over the past 5 years.
Undervalued
The company’s latest PE is -5.13, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 350.93K shares, increasing 46.35% quarter-over-quarter.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
10.671
Target Price
+444.46%
Upside Space
Nervgen Pharma Ord Shs News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Nervgen Pharma Ord Shs Info
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Ticker SymbolNGEN
CompanyNervgen Pharma Ord Shs
CEORogers (Adam H)
Websitehttps://www.nervgen.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52818.700
-23.800 (-0.04%)
29612.700
+301.300 (+1.03%)
7497.800
+26.300 (+0.35%)
14949.000
+146.000 (+0.99%)
69494.000
+1346.000 (+1.98%)
6371.100
+18.300 (+0.29%)
68.603
+0.259 (+0.38%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4179.430
+57.520 (+1.40%)
FAQs
What is the current price of Nervgen Pharma Ord Shs (NGEN)?
The current price of Nervgen Pharma Ord Shs (NGEN) is 2.12.
What is the symbol of Nervgen Pharma Ord Shs?
The ticker symbol of Nervgen Pharma Ord Shs is NGEN.
What is the 52-week high of Nervgen Pharma Ord Shs?
The 52-week high of Nervgen Pharma Ord Shs is 6.30.
What is the 52-week low of Nervgen Pharma Ord Shs?
The 52-week low of Nervgen Pharma Ord Shs is 1.50.
What is the market capitalization of Nervgen Pharma Ord Shs?
The market capitalization of Nervgen Pharma Ord Shs is 168.86M.
Is Nervgen Pharma Ord Shs (NGEN) currently rated as Buy, Hold, or Sell?
According to analysts, Nervgen Pharma Ord Shs (NGEN) has an overall rating of Buy, with a price target of 10.67.
What is the Earnings Per Share (EPS TTM) of Nervgen Pharma Ord Shs (NGEN)?
The Earnings Per Share (EPS TTM) of Nervgen Pharma Ord Shs (NGEN) is -0.44.